Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)
Historic Non-Current Assets for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $31.6 million.
- Innate Pharma's Non-Current Assets fell 2635.2% to $31.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $31.6 million, marking a year-over-year decrease of 2635.2%. This contributed to the annual value of $27.1 million for FY2024, which is 747.31% down from last year.
- Latest data reveals that Innate Pharma reported Non-Current Assets of $31.6 million as of Q2 2025, which was down 2635.2% from $27.1 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Non-Current Assets ranged from a high of $164.4 million in Q2 2021 and a low of $27.1 million during Q4 2024
- For the 5-year period, Innate Pharma's Non-Current Assets averaged around $75.5 million, with its median value being $59.4 million (2023).
- Over the last 5 years, Innate Pharma's Non-Current Assets had its largest YoY gain of 744.08% in 2021, and its largest YoY loss of 9990.29% in 2021.
- Quarter analysis of 5 years shows Innate Pharma's Non-Current Assets stood at $147.8 million in 2021, then plummeted by 58.97% to $60.7 million in 2022, then plummeted by 51.81% to $29.2 million in 2023, then dropped by 7.47% to $27.1 million in 2024, then increased by 16.98% to $31.6 million in 2025.
- Its last three reported values are $31.6 million in Q2 2025, $27.1 million for Q4 2024, and $43.0 million during Q2 2024.